Collegium Pharmaceutical, Inc. Incremental Common Shares Attributable to Dilutive Effect of Conversion of Preferred Stock
Collegium Pharmaceutical, Inc. (COLL) reported Incremental Common Shares Attributable to Dilutive Effect of Conversion of Preferred Stock of 6.55 million shares for the 3-month period ending 2015-03-31, per its 10-Q filed 2016-05-11.
Discontinued › Income Statement › Earnings Per Share
us-gaap:IncrementalCommonSharesAttributableToConversionOfPreferredStock · last filed 2016-05-11
- Collegium Pharmaceutical, Inc. incremental common shares attributable to dilutive effect of conversion of preferred stock for the quarter ending 2015-03-31 was 6.55M shares.
| Period end | Incremental Common Shares Attributable to Dilutive Effect of Conversion of Preferred Stock 3 month |
|---|---|
| 2015-03-31 | 6.55M shares 10-Q · filed 2016-05-11 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Faeth Therapeutics, Inc. (FTH) | United States | $0.750B | |
| Design Therapeutics, Inc. (DSGN) | United States | $0.766B | -12.78 |
| Verastem, Inc. (VSTM) | United States | $0.706B | -1.71 |
| Nuvectis Pharma, Inc. (NVCT) | United States | $0.705B | -17.53 |
| IRONWOOD PHARMACEUTICALS INC (IRWD) | United States | $0.694B | 5.37 |
| Wave Life Sciences, Inc. (WVE) | $0.780B | -5.56 | |
| Olema Pharmaceuticals, Inc. (OLMA) | United States | $0.790B | -5.35 |
| Climb Bio, Inc. (CLYM) | United States | $0.683B | -13.03 |
| Aclaris Therapeutics, Inc. (ACRS) | United States | $0.792B | -9.78 |
| GERON CORP (GERN) | United States | $0.803B | -12.14 |